Progyny, Inc.
Every calculator, already run for PGNY
Open the full toolkit →You have the numbers on PGNY. Get the argument.
A written report on which of these readings actually decide the outcome for Progyny, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering PGNYAnalyst Price Target Disagreement for Progyny, Inc.
Wall Street's bull case implies +59% from the current price; the bear case implies +19%. A 40% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for PGNY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In additi…
PGNY — frequently asked
Is PGNY a buy right now?
Wall Street's consensus rating on Progyny, Inc. is none across 12 analysts, with a mean price target of $34.42 (+37% vs. the current $25.19). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is PGNY overvalued?
PGNY trades at 27.4x trailing earnings, against a DCF fair value of $51 per share. The current price implies -4% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is PGNY's next earnings date?
Progyny, Inc. is next scheduled to report earnings around Nov 5, 2026. A full PGNY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Progyny, Inc.?
Analysts covering Progyny, Inc. (PGNY) range from a bear-case target of $30.00 to a bull-case high of $40.00, with a mean consensus target of $34.42 across 12 analysts. The spread of $10.00 (40% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Progyny, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Progyny, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PGNY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Progyny, Inc., in minutes. 3 free reports included with every account — no credit card required.